Two organizations that have each carved out influential positions in the global reproductive healthcare sector are joining forces. Sapyen, a global leader in male fertility diagnostics, and My Surrogacy Journey, a widely respected international surrogacy organization, announced on June 4, 2026, a strategic partnership aimed at expanding fertility testing and reproductive health support for intended parents throughout the United States.

The collaboration designates Sapyen as a fertility diagnostics partner for My Surrogacy Journey and its client base of intended parents worldwide. Services covered under the agreement include semen analysis, DNA fragmentation testing, and infectious disease screening, diagnostics that sit at the heart of any well-managed reproductive care pathway and that have historically been difficult to access in a streamlined, cross-border context.

A System Built for Another Era

To understand why this partnership matters, it helps to understand what it is responding to. For many years, the infrastructure around fertility testing and reproductive health has been fragmented, clinic-dependent, and logistically cumbersome, particularly for patients managing care across multiple countries. Those challenges are magnified in surrogacy journeys, where intended parents may be simultaneously coordinating with laboratories, clinics, legal professionals, and service providers operating under different regulatory systems in different jurisdictions.

Both Sapyen and My Surrogacy Journey share a common diagnosis: that the future of fertility care requires integrated global infrastructure, not isolated services. Patients should be able to move efficiently and reliably through reproductive pathways regardless of geography, without the delays and inconsistencies that have long characterized cross-border reproductive medicine.

What Each Organization Brings

My Surrogacy Journey has built its reputation through the careful construction of a curated global network, a rigorous commitment to ethical practice, patient advocacy, and the operational ability to manage extraordinarily complex cross-border journeys. It is widely recognized among both intended parents and fertility professionals as an organization that has brought greater transparency, consistency, and operational excellence to a sector that has historically lacked standardization.

Sapyen's contribution comes from a different but complementary direction. The company has developed significant infrastructure within fertility diagnostics and reproductive preservation, working alongside IVF clinic networks, laboratory organizations, benefits providers, and healthcare partners around the world. Its proprietary SPX72 stabilization technology represents a meaningful technical advance — extending the viability of analyzable semen samples from approximately one hour to as long as 72 hours. That extension makes laboratory-grade fertility testing and preservation practically achievable without the time and location constraints that have historically confined male fertility diagnostics to clinic-based collection settings.

The Vision Behind the Partnership

Ash Ramachandran, Founder and CEO of Sapyen, framed the conceptual shift driving the collaboration with characteristic directness. "The historical fertility model was built around geography. Patients travelled to infrastructure. The next generation of reproductive medicine will invert that entirely."

He also addressed the specific complexities of surrogacy as a reproductive medicine context. "Surrogacy is one of the most operationally complex categories in reproductive medicine. It requires coordination across clinicians, laboratories, legal teams, donors, intended parents, and international jurisdictions simultaneously. Infrastructure quality materially impacts patient outcomes in that environment. My Surrogacy Journey has built one of the most sophisticated and trusted platforms globally for navigating that complexity. They are not simply facilitating introductions. They are helping define the operational and ethical standard for modern surrogacy internationally."

Ramachandran's broader observation about where fertility testing and reproductive health services are heading is worth noting. "For decades, fertility testing and preservation were positioned as reactive services. By the time many patients entered the system, optionality had already narrowed. We believe that changes now. Earlier diagnostics, better biological data, and accessible preservation infrastructure will increasingly become standard entry points into reproductive medicine globally."

That repositioning, from reactive to proactive, from clinic-bound to globally accessible, captures the essential shift this partnership is designed to accelerate.

A Shared Commitment to Intended Parents

The response from the leadership of My Surrogacy Journey was equally focused on what the partnership means for the families the organization serves.

Michael Johnson-Ellis, Co-founder and Co-CEO of My Surrogacy Journey, described the terms on which the collaboration was pursued. "Our responsibility to intended parents extends far beyond guidance. We are building an ecosystem around them capable of supporting extraordinarily complex journeys with consistency, credibility, and care. Sapyen immediately distinguished itself with both its scientific credibility and operational capability to execute fertility diagnostics and preservation at international scale. Their infrastructure, laboratory integration, and long-term vision for modern fertility care make them an exceptionally strong partner for My Surrogacy Journey and for the families we support across the world."

Wes Johnson-Ellis, Co-founder and Co-CEO of My Surrogacy Journey, emphasized the cross-border dimension that makes this kind of partnership so necessary. "Intended parents today are navigating fertility across multiple countries and healthcare systems simultaneously. That requires partners capable of operating with precision internationally. This partnership materially strengthens the level of fertility support available to intended parents navigating increasingly global reproductive pathways."

Rolling Out Across the U.S. — With More to Come

The partnership will launch initially across the United States, targeting the large domestic intended parent population that works with My Surrogacy Journey's network. Over time, both organizations have indicated plans to explore additional collaboration in fertility preservation and broader fertility testing and reproductive health services.

For Sapyen, the agreement represents a further expansion of its international presence in fertility diagnostics, adding surrogacy-focused service delivery to its existing work across IVF clinic networks, laboratory organizations, and reproductive healthcare partners worldwide. For My Surrogacy Journey, it strengthens the completeness of the support ecosystem it offers to intended parents at a time when the operational demands of international surrogacy journeys are only becoming more complex.

Taken together, the partnership signals something larger: that the most consequential improvements in reproductive healthcare over the coming years will come not only from clinical innovation but also from the organizational infrastructure that determines how and where patients can actually access that care.